/ Unknown statusPhase 1/2IIT Evaluation of Safety and Efficacy of Transplantation of Autologous Hematopoietic Stem Cell Genetically Modified in Beta-Thalassemia Major
This is a single group, open label study in 10 subjects who are 8 years of age or older with beta-thalassemia major. The objective of this study is to evaluate the safety and efficacy of autologous hematopoietic stem cell transduced with lentiviral vector for the treatment of beta-thalassemia major.
100 Clinical Results associated with Guangdong Iridium Gene Technology Co., Ltd.
0 Patents (Medical) associated with Guangdong Iridium Gene Technology Co., Ltd.
100 Deals associated with Guangdong Iridium Gene Technology Co., Ltd.
100 Translational Medicine associated with Guangdong Iridium Gene Technology Co., Ltd.